RTW Biotech Opportunities Ltd (LSE: RTWG), an investment fund focused on the biopharmaceutical and medical technology sectors, has announced the repurchase of 100,000 of its Ordinary Shares at a price of $2.34 per share, executed on 6 November 2026. The repurchased shares will be held in treasury and will carry no voting rights, reducing the total voting rights in the company to 319,055,347. The buyback was conducted under authority granted by shareholders at the company's Annual General Meeting in June 2026, with Jefferies International Limited acting as broker for the transaction.

Key Points

  • RTW Biotech Opportunities Ltd (LSE: RTWG) is an investment fund managed by RTW Investments, LP, targeting biopharmaceutical and medical technology assets
  • The company repurchased 100,000 Ordinary Shares on 6 November 2026 at $2.34 per share, to be held in treasury
  • Total issued Ordinary Share capital stands at 345,967,440, with 26,912,093 shares now held in treasury; voting rights total 319,055,347
  • Investors should watch for further buyback activity under the existing AGM authority, which remains in force until the 2027 Annual General Meeting or until revoked

RTW Biotech Repurchases 100,000 Shares at $2.34 Under June 2026 AGM Mandate

The announcement confirms that RTW Biotech Opportunities Ltd completed the repurchase of 100,000 Ordinary Shares on 6 November 2026, paying $2.34 per share. The buyback was carried out under authority approved by shareholders at the company's Annual General Meeting held in June 2026. That mandate permits the company to repurchase a maximum of 14.99% of its Ordinary Shares in issue. The company noted that the actual number of shares repurchased will depend on prevailing market conditions, and the authority remains valid until a new shareholder mandate is granted, expected at the 2027 AGM, or until expressly revoked.

Treasury Holding Reduces RTW Biotech's Voting Share Count to 319,055,347

Following settlement of the transaction, RTW Biotech's total issued Ordinary Share capital stands at 345,967,440 shares, of which 26,912,093 are now held in treasury and attract no voting rights. This leaves a total of 319,055,347 voting rights in the company. The announcement specifies that this figure of 319,055,347 should be used by shareholders as the denominator when calculating whether they are required to disclose interests or changes to interests under the FCA's Disclosure and Transparency Rules. The company stated it is its current intention to continue holding any repurchased shares in treasury rather than cancelling them.

Jefferies International Acts as Broker With NAV Premium Restriction Applying

RTW Biotech has instructed Jefferies International Limited as its broker for buyback transactions, an arrangement the company states is in accordance with FCA Listing Rules and its general authority to repurchase shares. The company disclosed that no maximum consideration payable has been determined, but confirmed it cannot pay a price for any Ordinary Shares that would equate to a premium to net asset value. This restriction is a standard feature for investment companies conducting buybacks and is relevant context for investors monitoring the pace and pricing of any further repurchase activity under the existing mandate.

RTW Investments Manages Fund Focused on Next-Generation Therapies and Medical Technology

RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, described in the announcement as a healthcare-focused entrepreneurial investment firm with deep scientific expertise. The fund targets transformative assets with high growth potential across the biopharmaceutical and medical technology sectors, investing in companies developing next-generation therapies and technologies. The investment manager can be contacted through Oliver Kenyon and Krisha McCune for business, corporate development, and investor relations enquiries. Investors may be watching whether the fund continues to deploy its AGM buyback authority as a capital management tool in the months ahead.